ramosetron has been researched along with alosetron in 5 studies
| Studies (ramosetron) | Trials (ramosetron) | Recent Studies (post-2010) (ramosetron) | Studies (alosetron) | Trials (alosetron) | Recent Studies (post-2010) (alosetron) |
|---|---|---|---|---|---|
| 194 | 94 | 83 | 226 | 37 | 33 |
| Protein | Taxonomy | ramosetron (IC50) | alosetron (IC50) |
|---|---|---|---|
| Cytochrome P450 1A2 | Homo sapiens (human) | 5.3024 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.6 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 10 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 10 | |
| Cytochrome P450 2B6 | Homo sapiens (human) | 10 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 10 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.1 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 3.068 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, NM; Brady, CA; Butler, AS; Choo, SH; Cioffi, CL; Cohen, ML; Dobritsa, S; Earley, WG; Fitzpatrick, K; Guo, C; Guzzo, PR; Hassler, C; Manning, DD; Masih, L; Naginskaya, J; Ryan, KN; Sikkander, MI; Usyatinsky, A; Wierschke, JD; Zhang, Z | 1 |
| Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M | 1 |
| Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Sasamata, M; Takeuchi, A | 1 |
| Akuzawa, S; Funatsu, T; Hirata, T; Keto, Y; Miyata, K; Nakata, M; Sasamata, M; Takeuchi, A | 1 |
| Morgan, B | 1 |
5 other study(ies) available for ramosetron and alosetron
| Article | Year |
|---|---|
Novel serotonin type 3 receptor partial agonists for the potential treatment of irritable bowel syndrome.
Topics: Animals; Cell Line; Disease Models, Animal; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Mice; Microsomes, Liver; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Agonists | 2011 |
Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
Topics: Animals; Benzimidazoles; Carbazoles; Carbolines; Carrier Proteins; Colon; Defecation; Gastrointestinal Agents; Guinea Pigs; Humans; Ion Channels; Irritable Bowel Syndrome; Loperamide; Male; Muscle, Smooth; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Serotonin; Receptors, Serotonin, 5-HT3; Restraint, Physical; Serotonin Antagonists; Stress, Psychological | 2007 |
Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
Topics: Animals; Behavior, Animal; Benzimidazoles; Carbazoles; Carbolines; Colon; Colonic Diseases, Functional; Conditioning, Psychological; Corticotropin-Releasing Hormone; Defecation; Disease Models, Animal; Dose-Response Relationship, Drug; Fear; Gastrointestinal Transit; Immobilization; Irritable Bowel Syndrome; Loperamide; Male; Peptide Fragments; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Stress, Psychological; Time Factors; Treatment Outcome | 2007 |
Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.
Topics: Animals; Antidiarrheals; Benzimidazoles; Carbazoles; Carbolines; Colon; Corticotropin-Releasing Hormone; Defecation; Dose-Response Relationship, Drug; Injections, Intraventricular; Loperamide; Male; Pyridines; Rats; Rats, Wistar; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Water | 2008 |
Drug development: A healthy pipeline.
Topics: Animals; Benzimidazoles; Benzofurans; Bile Acids and Salts; Carbolines; Colesevelam Hydrochloride; Colestipol; Disease Models, Animal; Enteric Nervous System; Female; Humans; Imidazoles; Indoles; Irritable Bowel Syndrome; Loperamide; Lubiprostone; Male; Mice; Natriuretic Peptides; Peptides; Phenylalanine; Receptors, Serotonin, 5-HT3; Receptors, Serotonin, 5-HT4; Rifamycins; Rifaximin; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Visceral Pain | 2016 |